Cy­ti­va's lat­est project to open in Switzer­land at the end of the month

Glob­al life sci­ences com­pa­ny Cy­ti­va hasn’t been shy about its plans to pump mon­ey in­to ex­pand­ing glob­al op­er­a­tions. Tues­day, it an­nounced that it would open the doors at its lat­est big man­u­fac­tur­ing site in Eu­rope in a move that will quadru­ple its man­u­fac­tur­ing ca­pac­i­ty.

Cy­ti­va’s new site in Grens, Switzer­land will house its Cen­ter of Ex­cel­lence for cell and gene ther­a­pies and will be used in reg­u­la­to­ry-ap­proved ther­a­pies and clin­i­cal tri­als.

The near­ly 80,000 square-feet site will be open for busi­ness on May 31. The site will man­u­fac­ture sin­gle-use kits for Sep­ax and Se­fia cell pro­cess­ing sys­tems, and con­sum­ables for Xuri cell ex­pan­sion sys­tems. It will al­so serve as a home base for Eu­ro­pean cus­tomers and their train­ing pro­grams. 250 em­ploy­ees are set to work here at the start. A ground­break­ing cer­e­mo­ny will be held on May 31 to mark the event.

Cata­ri­na Fly­borg

“Cell and gene ther­a­pies have the po­ten­tial to change the glob­al health­care land­scape,” said Cata­ri­na Fly­borg VP of C&G Ther­a­py at Cy­ti­va. “Our new fa­cil­i­ty in Grens will en­able us to meet glob­al de­mand for our prod­ucts, while work­ing with our cus­tomers to meet their im­me­di­ate train­ing and de­vel­op­ment needs. This fa­cil­i­ty brings us an­oth­er step clos­er to our vi­sion where ac­cess to life-chang­ing ther­a­pies trans­forms hu­man health.”

The al­ready-ex­ist­ing site in Eysins will keep op­er­at­ing through the end of next year, while full pro­duc­tion is trans­ferred to the newest site in Grens. The new site has been built to Swiss Min­ergie stan­dards, and is pow­ered by 100% re­new­able elec­tric­i­ty and has mount­ed so­lar pan­els on the roof. The com­pa­ny said that the dy­nam­ic clean­room con­trols could re­duce the amount of en­er­gy it us­es by 60%.

Philippe Leu­ba

“Cy­ti­va is one of the world’s lead­ing life sci­ences com­pa­nies,” said Philippe Leu­ba, Switzer­land’s Min­is­ter of Eco­nom­ic Af­fairs, in a state­ment. “Its de­ci­sion to ex­pand op­er­a­tions in Switzer­land is a tes­ta­ment to our in­no­va­tion ecosys­tem that has played a sig­nif­i­cant role in de­vel­op­ing some of the most ad­vanced ther­a­peu­tics.”

Cy­ti­va has pledged $1.5 bil­lion to ex­pand its man­u­fac­tur­ing op­er­a­tions around the world, as it looks to shift the fo­cus to in-re­gion, for-re­gion man­u­fac­tur­ing. In March, it opened a new 118,400 square-foot site in Cardiff, Wales that’s fo­cused on man­u­fac­tur­ing sin­gle-use bio­pro­cess­ing tech. That site will serve cus­tomers around the world, but pro­vide cus­tomers in the UK and Eu­rope with a clos­er op­er­a­tion to work with. That site will fo­cus on Cy­ti­va’s can­cer, au­toim­mune and rare dis­ease drug clients, as well as Covid-19 vac­cines.

It al­so has pledged $52.5 mil­lion in South Ko­rea for the man­u­fac­tur­ing of cell cul­ture flu­id, which at the time, was in very short sup­ply. It ex­pand­ed two lo­ca­tions in cen­tral Mass­a­chu­setts in 2020 with the ad­di­tion of 130 new jobs in West­bor­ough and an up­grade at its Shrews­bury site too.

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

AJ Patel was recovering from a complicated brain surgery when his oncologist burst into the hospital room yelling, “I’ve got some really great news for you!”

For two years, Patel had been going from doctor to doctor trying to diagnose his wheezing, only to be dealt the devastating news that he had stage IV lung cancer and only six months to live. And then they found the brain tumors.

“What are you talking about?” Patel asked. He had never seen an oncologist so happy.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

(Credit: Shutterstock)

Cracks in the fa­cade: Is phar­ma's pan­dem­ic ‘feel good fac­tor’ wan­ing?

The discordant effects of the Covid-19 pandemic on pharma reputation continues. While the overall industry still retains a respectable halo from its Covid-19 quick response and leadership, a new patient group study reveals a different story emerging in the details.

On one hand, US patient advocacy groups rated the industry higher-than-ever overall. More than two-thirds (67%) of groups gave the industry a thumbs up for 2021, a whopping 10 percentage point increase over the year before, according to the PatientView annual study, now in its 9th year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Belén Garijo, Merck KGaA CEO (Kevin Wolf/AP Images for EMD Serono)

Mer­ck KGaA pumps €440M in­to ex­pand­ing and con­struct­ing Irish man­u­fac­tur­ing fa­cil­i­ties

The area of Ireland famous for Blarney Castle and its cliffsides along the Atlantic Ocean is seeing Merck KGaA expand its commitment there.

The German drug manufacturer is expanding its membrane and filtration manufacturing capabilities in Ireland. The company will invest approximately €440 million ($470 million) to increase membrane manufacturing capacity in Carrigtwohill, Ireland, and build a new manufacturing facility at Blarney Business Park, in County Cork, Ireland.

Phillip Gomez, SIGA CEO

UP­DAT­ED: On the back of SIGA Tech­nolo­gies' win with the FDA, the mon­key­pox virus sees the com­pa­ny spring­ing to fur­ther ac­tion

As the cases of monkeypox now sit at well over 100 worldwide and have spread to multiple continents, the orders for any type of vaccine against monkeypox are seeing nations and medical bodies looking to get their hands on anything and everything. And now SIGA Technologies seems to be getting in on the action.

According to Euronews, SIGA Technologies, a pharmaceutical company that is focused on providing medical countermeasures to biological and chemical attacks, is now in talks with several European authorities looking to stockpile its antiviral that can counter monkeypox. The drug known as tecovirimat or Tpoxx was approved by the FDA in 2018 as a vaccine for smallpox but was approved by the European Medicines Agency to also act against monkeypox, cowpox and complications from immunization with vaccinia.

Co­pay coupons gone wrong, again: Pfiz­er pays al­most $300K to set­tle com­plaints in four states

Pfizer has agreed to pay $290,000 to settle allegations of questionable copay coupon practices in Arizona, Colorado, Kansas, and Vermont from 2014 to 2018.

While the company has not admitted any wrongdoing as part of the settlement, Pfizer has agreed to issue restitution checks to about 5,000 consumers.

A Pfizer spokesperson said the company has “enhanced its co-pay coupons to alleviate the concerns raised by states and agreed to a $30,000 payment to each.”

Delaware court rules against Gilead and Astel­las in years-long patent case

A judge in Delaware has ruled against Astellas Pharma and Gilead in a long-running patent case over Pfizer-onwed Hospira’s generic version of Lexiscan.

The case kicked off in 2018, after Hospira submitted an Abbreviated New Drug Application (ANDA) for approval to market a generic version of Gilead’s Lexiscan. The drug is used in myocardial perfusion imaging (MPI), a type of nuclear stress test.

Taye Diggs (courtesy Idorsia)

Idor­sia inks an­oth­er celebri­ty en­dors­er deal with ac­tor and dad Taye Dig­gs as Qu­viviq in­som­nia am­bas­sador

Idorsia’s latest Quviviq insomnia campaign details the relatable dad story of a well-known celebrity — actor and Broadway star Taye Diggs.

Diggs stopped sleeping well after the birth of his son, now more than 10 years ago. Switching mom-and-dad nightly shifts to take care of a baby interrupted his sleep patterns and led to insomnia.

“When you’re lucky enough to be living out your dream and doing what you want, but because of something as simple as a lack of sleep, you’re unable to do that, it felt absolutely — it was treacherous,” he says in an interview-style video on the Quviviq website.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Rep. Katie Porter (D-CA) (Michael Brochstein/Sipa USA/Sipa via AP Images)

House Dems to Sen­ate lead­er­ship: Quick­ly move a rec­on­cil­i­a­tion bill with drug price ne­go­ti­a­tion re­forms

Twenty House Democrats, including Reps. Katie Porter of California and Susan Wild of Pennsylvania, are calling on Senate leaders to move quickly with a reconciliation bill (meaning they only need a simple majority for passage) with prescription drug pricing reforms, and to include adding new authority for Medicare to negotiate drug prices.

They also called on the Senate to specifically follow suit with the House passage of a $35 per month insulin cap (as Senate Majority Leader Chuck Schumer’s deadline for a vote on that provision has come and gone), and to cap Medicare Part D costs at $2,000 per year for seniors.

Bris­tol My­ers Squibb sues No­var­tis for roy­al­ties sur­round­ing the use of trans­genic mice

Two Big Pharma companies are going to the mat over genetically modified mice in a licensing dispute.

Bristol Myers Squibb is suing Novartis in New York over a dispute concerning an evaluation, research and commercialization agreement stretching back to the late ’90s initially inked between Novartis and BMS’ predecessor Medarex. The deal in question allowed Novartis to use Medarex’s patented transgenic mice to develop therapeutic drugs. Novartis agreed to pay Medarex – and subsequently BMS – a royalty on sales of drugs it developed using the mice.